- The FDA approves Amgen's (NASDAQ:AMGN) Nplate (romiplostim) for use in newly diagnosed adults with immune thrombocytopenia (ITP) (low blood platelets) who have not responded adequately to corticosteroids, immunoglobulins or splenectomy (spleen removal).
- The agency approved the thrombopoietin receptor agonist in August 2008 for the long-term treatment of adults with chronic ITP and in December 2018 for pediatric ITP patients.